Hikal Ltd vs Parmax Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Hikal Ltd is ₹ 196.55 as of 05 May 15:30 . The P/E Ratio of Hikal Ltd changed from 13.3 on March 2021 to 54.4 on March 2025 . This represents a CAGR of 32.54% over 5 yearsThe P/E Ratio of Parmax Pharma Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Hikal Ltd changed from ₹ 1769 crore on March 2021 to ₹ 4933 crore on March 2025 . This represents a CAGR of 22.76% over 5 yearsThe Market Cap of Parmax Pharma Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Hikal Ltd for the Dec '25 is ₹ 497.1 crore as compare to the Sep '25 revenue of ₹ 320.4 crore. This represent the growth of 55.15% The revenue of Parmax Pharma Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Hikal Ltd for the Dec '25 is ₹ 47.5 crore as compare to the Sep '25 ebitda of ₹ 9.1 crore. This represent the growth of 421.98% The ebitda of Parmax Pharma Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Hikal Ltd changed from ₹ 5.1 crore to ₹ -5.9 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Parmax Pharma Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Hikal Ltd changed from 18.52 % on March 2021 to 10.87 % on March 2025 . This represents a CAGR of -10.11% over 5 yearsThe Dividend Payout of Parmax Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Hikal Ltd

Hikal Limited, incorporated on July 8, 1988, has emerged as one of the preferred partners for global companies in segments such as pharmaceuticals, crop protection, animal health, biocides, and specialty chemicals.
The Company is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. The Company has 5 manufacturing facilities across three states in India.
It supply products to customers across the globe in the US, Japan, Europe, Canada, South East Asia, LATAM, India and RoW. Apart from this, it specialize in manufacturing APIs and intermediates in pharmaceutical division.
Within pharmaceutical division, it offer human health and animal health products. Hikal commenced its first project in 1991 at its first greenfield site at M.

About Parmax Pharma Ltd

Incorporated in Nov.'94, Parmax Pharma Ltd (PPL) was promoted by Jayantilal S Dhol, Purushottam J Bhalodi and Prabhudas D Hansalpara.
The Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations ( CMO) business are the key pillar of Parmax's pharmaceutical operations. The Promoters were earlier into manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc.
The Company then discontinued their business activities for few years due to various reasons.
Starting from their journey as a bulk drug manufacturer and speciality chemicals in 1994; the Company had set up a plant to manufacture and market bulk drugs like amoxycillin tri-hydrate, ampicillin tri-hydrate, cephalexin mono hydrate and nalidixic acid, at Hadamtala, Gujarat, with an installed capacity of 96 TPA.

FAQs for the comparison of Hikal Ltd and Parmax Pharma Ltd

Which company has a larger market capitalization, Hikal Ltd or Parmax Pharma Ltd?

Market cap of Hikal Ltd is 2,400 Cr while Market cap of Parmax Pharma Ltd is 12 Cr

What are the key factors driving the stock performance of Hikal Ltd and Parmax Pharma Ltd?

The stock performance of Hikal Ltd and Parmax Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Hikal Ltd and Parmax Pharma Ltd?

As of May 5, 2026, the Hikal Ltd stock price is INR ₹194.65. On the other hand, Parmax Pharma Ltd stock price is INR ₹32.5.

How do dividend payouts of Hikal Ltd and Parmax Pharma Ltd compare?

To compare the dividend payouts of Hikal Ltd and Parmax Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.